IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11541027 B1

PDFFull Text
Date of Patent:
Jan. 03, 2023

Filed:

May. 12, 2015

Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases

Applicant:

Delmar Pharmaceuticals, Inc., Vancouver, CA;

Inventors:

Jeffrey A. Bacha, Vancouver, CA;

Dennis M. Brown, Menlo Park, CA (US);

Anne Steinø, Vancouver, CA;

Assignee:

DEL MAR PHARMACEUTICALS (BC) LTD., Vancouver, CA;

Attorney:

Christensen O'Connor Johnson Kindness PLLC

Primary Examiner:

James D Anderson

Int. Cl.
CPC ...
A61K 31/336 (2006.01); A61K 33/243 (2019.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 9/08 (2006.01); A61K 9/16 (2006.01); A61K 9/127 (2006.01); A61K 9/48 (2006.01); A61K 9/20 (2006.01); A61K 9/06 (2006.01); A61K 9/10 (2006.01); A61K 9/02 (2006.01); A61K 31/04 (2006.01); A61K 9/19 (2006.01); A61K 9/70 (2006.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
A61K 31/336 (2013.01); A61K 9/00 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0056 (2013.01); A61K 9/0095 (2013.01); A61K 9/02 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/127 (2013.01); A61K 9/1605 (2013.01); A61K 9/19 (2013.01); A61K 9/2004 (2013.01); A61K 9/4808 (2013.01); A61K 9/5107 (2013.01); A61K 9/7023 (2013.01); A61K 31/04 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01);
Abstract

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates Nmethylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.

Find Patent Forward Citations

Loading…